{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-264875","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2022-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.889052+00:00","generated_at":"2026-06-23T02:35:18.272099+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Jazz licenses zanidatamab from Zymeworks for up to $1.76B; $50M upfront, $325M option payment","bullets":["Exclusive rights in U.S., Europe, Japan for HER2-targeted bispecific antibody zanidatamab.","Zymeworks eligible for $50M upfront, $325M option payment after HERIZON-BTC-01 data, plus up to $1.39B milestones.","Tiered royalties of 10%-20% on net sales; deal expected to close in 2022 subject to HSR clearance.","Zanidatamab in pivotal trials for biliary tract cancer and gastroesophageal adenocarcinoma.","FDA Breakthrough Therapy and Fast Track designations; top-line BTC data expected by end of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-264875","json":"https://secwatch.observer/filing/0001193125-22-264875.json","markdown":"https://secwatch.observer/filing/0001193125-22-264875.md","text":"https://secwatch.observer/filing/0001193125-22-264875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000119312522264875/0001193125-22-264875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000119312522264875/d496602d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:35:18.272099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}